Bio + Health

Going back to the workplace, in a pandemic; a Nobel Prize for CRISPR; Understanding aging might be the key to Alzheimer’s; and more

a16z editorial Posted October 29, 2020

Going back to the workplace, in a pandemic; a Nobel Prize for CRISPR; Understanding aging might be the key to Alzheimer’s; and more Table of Contents

This post first appeared as an issue of the a16z Bio Newsletter. Subscribe to stay on top of the latest trends in bio and healthcare.

IN THIS EDITION: 

  • Are we ready for the cure for cancer?
  • Understanding aging might be the key to Alzheimer’s
  • A Nobel Prize for CRISPR
  • Going back to the workplace, in a pandemic
  • Join the Bio Eats World Journal Club

Want more a16z?

Sign up to get our best articles, latest podcasts, and news on our investments emailed to you.

Loading form...

Thanks for signing up.

See All NewslettersBy clicking the Subscribe button, you agree to the Privacy Policy.

The cure for cancer might finally be coming -- and we aren't ready...

The science of treating cancer has never been more promising — as Gary Reedy (President of the American Cancer Association), Jonathan Lim (CEO and co-founder of Erasca), and Jorge Conde (a16z general partner) discussed with host Hanne Winarsky in this episode of our new podcast, Bio Eats World.

 

But even if we could cure all cancer tomorrow — say with engineered cell therapies like CAR T — our system could not yet handle actually getting the treatments to the patients who need it most. These medicines are both the most complex and the most impactful we’ve ever seen; you can’t pick them up in a pill bottle at your corner pharmacy. In this call to action, Jorge Conde describes the infrastructure we need to build today, and the issues we need to think through, in order to make sure we get these life-saving medicines to all patients, at scale, as soon as possible. 

Read the full article on the challenges of delivering cell and gene therapies at scale »

...While a new treatment for Alzheimer's might come from understanding aging

The discovery that deleting one gene in a tiny worm — suddenly increasing that worm’s lifespan — dramatically transformed the science of aging from a fringe field into a promising path to one day (hopefully) helping us all live longer, and healthier, lives. But understanding aging also has the potential to give us the best map of the promising drug targets for some of the most challenging age-related diseases, like Alzheimer’s. In this article, a16z general partner Vijay Pande and CEO and co-founder of BioAge Kristen Fortney, suggest that our best route towards breakthroughs for these diseases is in treating the biggest risk factor: aging. And in this related episode of the Bio Eats World podcast, Longevity Fund Founder Laura Deming joins Fortney and Pande to discuss with host Hanne Winarsky where we are in the science of aging, and where it might lead us.

 

Read more about how slowing aging slows age-related diseases »

A Nobel Prize for CRISPR

Earlier this month, Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for their discovery and development of the CRISPR/Cas9 method for genome editing. On our news show, 16 Minutes, Vijay Pande and Jorge Conde talk to host Sonal Chokshi about this momentous occasion and what it means for the field. While CRISPR is often described as “genetic scissors” (i.e. a tool), the real promise of CRISPR is its application as a gene-editing platform. As Jorge Conde describes in the episode, CRISPR is a swiss-army knife, and we have only just accessed the scissors — but there is so much more it can do.

Listen to the full episode »

Going back to the workplace, in a pandemic:

In the Before Times, for the vast majority of us, talking to your employer about your health was limited to understanding your benefits package. COVID-19 has changed this entirely, as employers now have to wrestle with whether to bring employees back, monitoring employee health, and preventing disease transmission. No one’s been preparing all their life to be a Chief Covid Officer — so how do employers make these critical decisions? What tools do they need? In this Bio Eats World episode, a16z general partner Vineeta Agarwala, Phong Nguyen (EVP and General Manager at Accolade), Ryan Sandler (CEO and co-founder of Truework), and Mark Sendak (Population Health & Data Science Lead at the Duke Institute for Health Innovation) discuss how employers can think about this — a framework of prevent, triage, trust (and then test, trace, isolate); tools to incorporate and manage data from tests, surveys, and temperature checks; the tech we have, and where we need human expertise to help; privacy and trust around this sensitive health data; and much more. 

Listen to the full episode »

Join the Bio Eats World Journal Club

Every Thursday on our new podcast Bio Eats World, host Lauren Richardson dives deep into a new scientific article with experts, discussing the key implications of the breakthrough research and how to translate these new insights from paper to practice. So far, we’ve covered: 

We want to hear from you. What have we missed? What is coming next? Email us at bioeatsworld@a16z.com

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.